# OnCo record telimet-nsclc-01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/telimet-nsclc-01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "telimet-nsclc-01", "NCT04928846" ;
  schema:name "TeliMET NSCLC-01"@en ;
  schema:description "The confirmatory trial for the first c-MET ADC, which was approved early on response rate alone."@en ;
  schema:url <https://onco.cc/trials/telimet-nsclc-01/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04928846> ;
  onco:status "recruiting" ;
  onco:phase "3" ;
  schema:startDate "2022-03-25" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .